Source-grounded facts extracted from FILANA THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.
“Proposal Four – The 2025 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 7,487,142 2,827,840 100,494 14,144,300”
FILANA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-11 meeting.
“Proposal Three – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026, was ratified based upon the following votes: For Against Abstain 22,671,610 1,408,513 479,653”
FILANA THERAPEUTICS, INC. shareholders approved Amendment to the 2018 Omnibus Incentive Plan at the 2026-06-11 meeting.
“Proposal Two – An amendment to the Company’s 2018 Omnibus Incentive Plan was approved based upon the following votes: For Against Abstain Broker Non -Vote 8,427,565 1,869,290 118,621 14,144,300”
FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2026-06-11 meeting.
“Proposal One – Three (3) nominees for election or re-election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Richard J. Barry 8,851,285 1,564,191 14,144,300 Pierre Gravier 9,069,595 1,345,881 14,144,300 Claude Nicaise, M.D. 8,924,355 1,491,121 14,144,300”
FILANA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: net income $10.3 million, EPS $0.21 per share.
“Net loss was $10.3 million, or $0.21 per share.”
FILANA THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss for 2025 was $91.0 million, EPS $1.88 per share.
“Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results”
FILANA THERAPEUTICS, INC.: Adopted amended and restated By-Laws reflecting the name change and clarifying provisions on stockholder and board meetings, advance notice, director terms, special meetings, inspectors of election, and uncertificated shares (effective 2026-03-10).
“The Company’s board of directors also adopted amended and restated By-Laws of the Company (“Amended By-Laws”) reflecting the Name Change, effective as of March 10, 2026.”
FILANA THERAPEUTICS, INC.: Company changed its legal name to Filana Therapeutics, Inc. via amendment to Restated Certificate of Incorporation (effective 2026-03-10).
“Effective March 10, 2026, Cassava Sciences, Inc. changed its legal name (the “Name Change”) to Filana Therapeutics, Inc. (the “Company”).”
R. Christopher Cook was appointed as Chief Operating and Legal Officer at FILANA THERAPEUTICS, INC..
“On April 18, 2025, Mr. Cook, previously our Senior Vice President and General Counsel, was appointed Chief Operating and Legal Officer of the Company.”
James W. Kupiec resigned as Chief Medical Officer at FILANA THERAPEUTICS, INC..
“On April 15, 2025, James W. Kupiec, M.D. informed Cassava Sciences, Inc. (the “Company”) of his intent to retire and tendered his resignation as the Company’s Chief Medical Officer, effective as of May 9, 2025.”
FILANA THERAPEUTICS, INC. announced a restructuring with charges of approximately $0.4 million (10 employees, a reduction of 33%).
“The Company estimates that it will incur approximately $0.4 million of one-time costs in connection with the Workforce Reduction, primarily related to severance payments.”
Claude Nicaise was appointed as Chairman at FILANA THERAPEUTICS, INC..
“the Board has appointed Claude Nicaise, M.D., as its Chairman.”
Richard (Rick) Barry was appointed as Chief Executive Officer at FILANA THERAPEUTICS, INC..
“On September 9, 2024, Cassava Sciences, Inc. (“Cassava” or the “Company”) announced that the Company’s Board of Directors has concluded its search for a Chief Executive Officer (“CEO”) and has appointed Richard (Rick) Barry as the Company’s CEO.”
Richard J. Barry was appointed as Executive Chairman at FILANA THERAPEUTICS, INC..
“On July 15, 2024, Richard J. Barry, an independent director and currently the Chair of the Company’s Audit and Nominating & Governance Committees, was appointed by the Board as its Executive Chairman.”
Remi Barbier resigned as Chairman of the Board at FILANA THERAPEUTICS, INC..
“In addition, on July 15, 2024, the Company’s Board of Directors (the “ Board ”) accepted Mr. Barbier’s resignation as Chairman of the Board and from board membership, effective immediately.”
Remi Barbier resigned as President and Chief Executive Officer at FILANA THERAPEUTICS, INC..
“On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024”
FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on 2023 executive compensation at the 2024-05-09 meeting.
“The 2023 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 9,403,571 1,338,907 526,173 15,710,817”
FILANA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-09 meeting.
“The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following votes: For Against Abstain 26,461,553 380,036 137,879”
FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2024-05-09 meeting.
“Three (3) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Remi Barbier 10,768,599 500,052 15,710,817 Sanford R. Robertson 8,944,665 2,323,986 15,710,817 Patrick J. Scannon, M.D., Ph.D. 10,891,367 377,284 15,710,817”
FILANA THERAPEUTICS, INC. reported full year ended December 31, 2023 results: net income net loss of $97.2 million, EPS loss of $2.32 per share.
“Net loss for full year 2023 was $97.2 million, or $2.32 per share, compared to a net loss of $76.2 million, or $1.90 per share, in 2022.”
FILANA THERAPEUTICS, INC. entered into Warrant Agreement with Computershare Inc. and Computershare Trust Company, N.A. valued at Warrants to purchase shares of Common Stock at an Exercise Price of $33.00 per Warrant, with a Bonus (effective 2024-01-03).
“On December 12, 2023, Cassava Sciences, Inc., a Delaware corporation (the " Company "), announced that the Board of Directors of the Company declared a distribution (the " Warrant Distribution ") to the holders of record of the Company's shares of common stock, par value $0.001 per share (the " Common Stock "), in the form of warrants to purchase shares of Common Stock (the " Warrants ").”
FILANA THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income $25.7 million, or $0.61 per share, EPS $0.61 per share.
“Net loss was $25.7 million, or $0.61 per share. This compares to a net loss of $20.3 million, or $0.51 per share, for the same period in 2022.”
FILANA THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on frequency of advisory votes on executive compensation at the 2023-05-04 meeting.
“Proposal Six – A non-binding, advisory vote on the frequency of non-binding, advisory votes on the executive compensation for the Company’s named executive officers was approved for every “one” year based upon the following votes: Every one year Every two years Every three years Abstain Broker Non -Vote 8,154,665 151,642 336,776 318,422 15,811,623”
FILANA THERAPEUTICS, INC. shareholders approved 2022 executive compensation for named executive officers (non-binding advisory vote) at the 2023-05-04 meeting.
“Proposal Five – The 2022 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 6,604,493 2,105,630 251,382 15,811,623”
FILANA THERAPEUTICS, INC. shareholders approved Appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-04 meeting.
“Proposal Four – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023, was ratified based upon the following votes: For Against Abstain 24,121,878 532,002 119,248”
FILANA THERAPEUTICS, INC. shareholders approved Company's Non-employee Director Compensation Program at the 2023-05-04 meeting.
“Proposal Three – The Company’s Non-employee Director Compensation Program was approved based upon the following votes: For Against Abstain Broker Non -Vote 7,758,563 985,705 217,237 15,811,623”
FILANA THERAPEUTICS, INC. shareholders rejected Amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company at the 2023-05-04 meeting.
“Proposal Two – An amendment to the Company’s Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company , which received approximately 87% of the votes cast, did not receive votes greater than 50% of outstanding common shares as of the Record Date and was thus not approved based upon the following votes: For Against Abstain Broker Non -Vote 7,795,721 944,106 221,678 15,811,623”
FILANA THERAPEUTICS, INC. shareholders approved Election of two nominees to the Board of Directors for a three-year term at the 2023-05-04 meeting.
“Proposal One – Two (2) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Robert Z. Gussin, Ph.D. 7,116,958 1,844,547 15,811,623 Richard J. Barry 6,675,746 2,285,759 15,811,623”
FILANA THERAPEUTICS, INC. updated its first half 2023 guidance (lowered).
“New guidance for net cash use in first half 2023 is expected to be $30 to $40 million, which is revised downward from our previous guidance of $45 to $50 million, due primarily to the timing of certain clinical payment obligations.”
FILANA THERAPEUTICS, INC. reported three months ended March 31, 2023 results: net income $24.3 million, EPS $0.58 per share.
“Net loss was $24.3 million, or $0.58 per share, compared to a net loss of $17.5 million, or $0.44 per share, for the same period in 2022.”
FILANA THERAPEUTICS, INC. entered into Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC valued at up to $200,000,000 (effective 2023-05-01).
“On May 1, 2023, the Company entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“Agent”), pursuant to which the Company may offer and sell, from time to time through or to the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $200,000,000 (the “Offering”).”
FILANA THERAPEUTICS, INC. terminated SVB Sales Agreement with SVB Securities LLC (f/k/a SVB Leerink LLC) valued at up to $100,000,000 (effective 2023-05-01).
“On April 26, 2023, the Company provided SVB with notice of termination of the SVB Sales Agreement, effective May 1, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.